Tirzepatide (Mounjaro / Zepbound / 穆桂諾)

Tirzepatide

共 4 個適應症評級

🔬 實證評級速查

🔵 A 中度證據Tirzepatide (Mounjaro / Zepbound / 穆桂諾) × 肥胖

白話說：證據中等，有一定的支持。

證據分數 76 分（滿分 100）　·　發布狀態：可參考，但附帶但書

🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

第三方營養資料庫（國際）
展開原文引用
「Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for obesity) developed by Eli Lilly, FDA-approved 2022/2023.」
US FDA 態度：支持
展開原文引用
「MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …」
EU EFSA 態度：支持
展開原文引用
「Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。產製日期 2026-06-09 ·　版本 v4。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查

🔵 A 中度證據Tirzepatide (Mounjaro / Zepbound / 穆桂諾) × 第二型糖尿病

白話說：證據中等，有一定的支持。

證據分數 76 分（滿分 100）　·　發布狀態：可正常參考

🔬 存在反面證據🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

第三方營養資料庫（國際）
展開原文引用
「Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for obesity) developed by Eli Lilly, FDA-approved 2022/2023.」
US FDA 態度：支持
展開原文引用
「MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …」
EU EFSA 態度：支持
展開原文引用
「Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…」

評級由多源健康證據引擎彙整（FDA／EFSA／NHS／TFDA／WHO／PubMed／NIH ODS 等多個官方與權威來源）。產製日期 2026-06-09 ·　版本 v5。本評級僅供衛教參考，不取代醫師診斷與處方。 · 查看此成分的完整評級 · 📊 證據資料庫原始頁面

🔬 實證評級速查

🔵 A 中度證據Tirzepatide (Mounjaro / Zepbound / 穆桂諾) × 睡眠呼吸中止 (OSA)

白話說：證據中等，有一定的支持。

證據分數 72 分（滿分 100）　·　發布狀態：可參考，但附帶但書

⚠️ 部分研究有廠商利益🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

第三方營養資料庫（國際）
展開原文引用
「Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for obesity) developed by Eli Lilly, FDA-approved 2022/2023.」
US FDA 態度：支持
展開原文引用
「MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …」
EU EFSA 態度：支持
展開原文引用
「Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…」

🔬 實證評級速查

🟡 B 初步證據Tirzepatide (Mounjaro / Zepbound / 穆桂諾) × 脂肪肝 MASLD/MASH

白話說：有初步證據，但研究規模還小，別當成定論。

證據分數 61 分（滿分 100）　·　發布狀態：可參考，但附帶但書

⚠️ 部分研究有廠商利益🇹🇼 台灣有獨立規範

這樣判讀，是參考了這些單位：

第三方營養資料庫（國際）
展開原文引用
「Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist (Mounjaro for type 2 diabetes, Zepbound for obesity) developed by Eli Lilly, FDA-approved 2022/2023.」
US FDA 態度：支持
展開原文引用
「MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS — Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell …」
EU EFSA 態度：支持
展開原文引用
「Mounjaro received a marketing authorisation valid throughout the EU on 15 September 2022. The active substance in Mounjaro, tirzepatide, acts in the same way as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Mounjaro is a prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct…」